Xtant Medical Holdings, Inc. (XTNT)

From the record

Xtant Medical Holdings, Inc.'s filings since 2017 show 7 warning events of 5 kinds: a debt default or acceleration notice (8-K item 2.04, the latest 2025-12-03); a notice about its exchange listing (8-K item 3.01, 2 times, the latest 2019-05-28); a warning not to rely on past financial statements (8-K item 4.02, the latest 2017-11-20); an auditor change (8-K item 4.01, 2 times, the latest 2023-08-18); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2017-11-09) (its current reports).

From the record

Xtant Medical Holdings, Inc.'s 8 filed years say what it did: revenue went from $72 million in fiscal 2018 to $134 million in fiscal 2025, up 9.2% a year; it rose in 5 of 7 years; the deepest fall was 26% from fiscal 2018 to fiscal 2020; net income was positive in 2 of 8 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Xtant Medical Holdings, Inc. earned about 10 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 90 cents per dollar of everything the company owns. Leverage: it owed about 46 cents per dollar of assets, and net share issuance: its share count grew 12.3% over the year (the filed statements).

From the record

Xtant Medical Holdings, Inc.'s standing among 109 graded names in its industry family: revenue of $134 million in fiscal 2025 ranks in the top 43% by size; a net margin of 3.7% ranks in the top 29%; revenue growth of 32.2% a year over the last 3 filed years ranks in the top 22% (its annual reports).

From the record

Xtant Medical Holdings, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Browne, Sean E (President and CEO, as filed), filing under that title since 2019-10-15, 7.1 years (top 33% of its family); the 8 officers and directors filing in the last fifteen months have been on the record a median of 4 years (bottom 24%); 2 officer or director changes were reported on Form 8-K since 2023-11-13, against the 8 people in charge now (top 17%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Xtant Medical Holdings, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $17 million against debt of $11 million leaves 6.4% of its assets as net cash, bottom 43% of its family; cash from operations less capital spending is 7.6% of revenue (top 27%); a gross margin of 62.9% (top 44%); research spending of 1.6% of revenue (bottom 5%) (its annual report).

From the record

Xtant Medical Holdings, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 32.2% a year over the last three filed years against 9.2% over all 8, speeding up (top 7% of its family); the newest year grew 14.2% (top 49%); research spending grew 31.9% a year (top 14%); capital spending grew 10.5% a year (top 35%) (its annual reports). Xtant Medical Holdings, Inc. reported 3 product lines in fiscal 2025: Orthobiologics at $73 million (54%), Spinal Implant at $42 million (32%), License at $19 million (14%); 2 of 3 grew against the year before (its annual report).

From the record

Xtant Medical Holdings, Inc.'s newest year against its own record: revenue of $134 million in fiscal 2025 came in 19.7% below the $167 million its prior three years' pace pointed to (bottom 22% of its family); net income of $5 million against a prior three-year average of $8 million (top 7%); a net margin of 3.7% against -9.3% before (top 44%) (its annual reports).